MWNA
ALXO icon

Marshall Wace North America’s ALX Oncology ALXO Stock Holding History

Marshall Wace North America’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-19,093
Closed -$1.04M – 1408
2021
Q2 		$1.04M Buy
+19,093
New +$1.14M ﹤0.01% 997

Other funds holding ALXO

VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Marshall Wace North America's ALXO Position: Q3 2021 in Review

Marshall Wace North America sold out of ALX Oncology (ALXO) in Q3 2021, closing a stake of 19,093 shares — an estimated $1.04M sold.

Marshall Wace North America first reported a position in ALXO in Q2 2021 and held it in 1 quarter. The position peaked at $1.04M in Q2 2021. 114 funds tracked by Wall St. Rank hold ALXO as of Q3 2021.

  • Marshall Wace North America reported no remaining ALX Oncology position as of Q3 2021 after selling out during the quarter.
  • Marshall Wace North America sold 19,093 ALX Oncology shares in Q3 2021, an estimated $1.04M.
  • Marshall Wace North America first reported a position in ALX Oncology in Q2 2021 and held it in 1 quarter.
  • Marshall Wace North America's ALX Oncology position peaked at $1.04M in Q2 2021.
  • 114 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.